$ACET News
Last published 1d ago
- 1d agoACETGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - ADICET BIO INCEarnings Call TranscriptsOne of the biotech analysts here at Guggenheim, and it's my pleasure to introduce our next company Adizet Bio, and with us we have the CEO, Ken Shore. Welcome Ken, and its a pleasure to have you here. So maybe just to se
- 6d agoACETAdicet Bio, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoACETAdicet Bio to Participate in Upcoming Investor ConferencesBusiness WireAdicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and
- 1mo agoACETAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)Business WireAdicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and
- 1mo agoACETAdicet Bio Prula-cel Clinical Data Update - ADICET BIO INCEarnings Call TranscriptsHello everyone and welcome to the Addisit webcast. All participants are currently in listen-only mode. Following the formal remarks from the company, the call will be opened up for Q&A. This call is being recorded and th
- 1mo agoACETADICET BIO PRULA-CEL CLINICAL DATA UPDATE - ADICET BIO INCEarnings Call TranscriptsHello everyone and welcome to the Addisit webcast. All participants are currently in listen-only mode. Following the formal remarks from the company, the call will be opened up for Q&A. This call is being recorded and th
- 1mo agoACETADICET BIO PRULA-CEL CLINICAL DATA UPDATE - ADICET BIO INCEarnings Call TranscriptsHello everyone and welcome to the Addisit webcast. All participants are currently in listen-only mode. Following the formal remarks from the company, the call will be opened up for Q&A. This call is being recorded and th
- 1mo agoACETAdicet Bio Prula-cel Clinical Data Update - ADICET BIO INCEarnings Call TranscriptsHello everyone and welcome to the Addisit webcast. All participants are currently in listen-only mode. Following the formal remarks from the company, the call will be opened up for Q&A. This call is being recorded and th
- 1mo agoACETAdicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus NephritisBusiness Wire- Prula-cel shown to be generally well tolerated with no CRS greater than Grade 2 and no IEC-HS or ICANS - -At 12-months, 54% of evaluable patients achieved DORIS remission and 50% of patients achieved CRR- -All
- 1mo agoACETAdicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus NephritisBusiness WireAdicet Bio, Inc. (NASDAQ:ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and
- 2mo agoACETAdicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate UpdateBusiness WirePrula-cel topline results from planned analysis expected September 2026 FDA clearance of IND for ADI-212 in mCRPC; Phase 1 clinical study expected to initiate in 4Q 2026 Unveiling next-generation in vivo CAR-T
- 2mo agoACETAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)Business WireAdicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and
- 2mo agoACETAdicet Bio Announces FDA Clearance of IND Application for ADI-212Business WirePhase 1 study in patients with mCRPC expected to begin enrollment in the fourth quarter of 2026 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta
- 3mo agoACETCG 46TH ANNUAL GROWTH CONFERENCE - ADICET BIO INCEarnings Call TranscriptsHey, great. Good morning, everybody, and thank you very much for joining us at the 46th Annual Canaccord Genuity Growth Conference. I'm John Newman, one of the senior biotech analysts here at the firm. So we're very exci
- 3mo agoACETCG 46TH ANNUAL GROWTH CONFERENCE - ADICET BIO INCEarnings Call TranscriptsHey, great. Good morning, everybody, and thank you very much for joining us at the 46th Annual Canaccord Genuity Growth Conference. I'm John Newman, one of the senior biotech analysts here at the firm. So we're very exci
- 3mo agoACETAdicet Bio Reports Second Quarter 2026 Financial Results and Provides Business UpdatesBusiness WireCompany to provide a comprehensive Phase 1 clinical update for prulacabtagene leucel (prula-cel, formerly ADI-001), featuring data from 22 patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE) with
- 3mo agoLPCNAPREACETLipocine Appoints Michael J. Grissinger to Board of DirectorsPR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective...
- 3mo agoACETAdicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth ConferenceBusiness WireAdicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President
- 6mo agoACETAdicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare ConferenceBusiness WireAdicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President
- 6mo agoACETAdicet Bio Reports First Quarter 2026 Financial Results and Provides Business UpdatesBusiness WireClinical update anticipated in mid-2026 for Phase 1 autoimmune program evaluating prulacabtagene leucel (prula-cel, formerly ADI-001) with at least 20 lupus nephritis (LN) and systemic lupus erythematosus (SLE) patients
- 8mo agoACETAdicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company ProgressBusiness WireStrong enrollment momentum in Phase 1 autoimmune program evaluating prulacabtagene leucel (prula-cel, formerly ADI-001); clinical update expected in 1H/2026 with an additional update in 2H/2026 Achieved regulatory
- 9mo agoACETAdicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026Business WireAdicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President
- 10mo agoACETAdicet Bio Announces Reverse Stock SplitBusiness WireAdicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that its board of directors
- 11mo agoACETAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)Business WireAdicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement
- 1y agoACETAdicet Bio Reports Third Quarter 2025 Financial Results and Provides Business UpdatesBusiness WireAnnounced positive preliminary safety and efficacy data from Phase 1 clinical trial of ADI-001 in patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE); data highlighted rapid and sustained
- 1y agoACETAdicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Business WireAdicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards
- 1y agoACETAdicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation ConferenceBusiness WireAdicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President
- 1y agoACETAdicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)Business WirePreliminary clinical data from the Phase 1 trial expected in 2H/2026 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for
- 1y agoACETAdicet Bio, Inc. Announces $80 Million Registered Direct OfferingBusiness WireAdicet Bio, Inc. ("Adicet") (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the pricing of an
- 1y agoACETAdicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)Business Wire-Clinical data to date supports a potentially transformational approach to treating autoimmune diseases with an off-the-shelf, one-time therapy- -As of the August 31, 2025 data cut-off date, all seven evaluable LN and
- 1y agoACETAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)Business WireAdicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement
- 1y agoACETAdicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceBusiness WireAdicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President
- 1y agoACETAdicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Business WireAdicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards
- 1y agoACETAdicet Bio Reports Second Quarter 2025 Financial Results and Provides Business UpdatesBusiness WireActively enrolling patients with lupus nephritis (LN), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) in Phase 1 clinical trial of ADI-001 in autoimmune diseases On track to report preliminary
- 1y agoACETAdicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth ConferenceBusiness WireAdicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President
- 1y agoACETAdicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune DiseasesBusiness WirePhase 1 clinical trial of ADI-001 in autoimmune diseases actively enrolling patients with lupus nephritis (LN), systemic lupus erythematosus (SLE) and SSc Preliminary clinical data from Phase 1 trial of ADI-001 in
- 1y agoACETAdicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare ConferenceBusiness WireAdicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President
- 1y agoACETAPREAdicet Bio Reports First Quarter 2025 Financial Results and Provides Business UpdatesBusiness WireTwo programs with clinical data readouts in 2H/2025 Phase 1 clinical trial of ADI-001 in autoimmune diseases ongoing with preliminary clinical data expected in 2H/2025; Trial now open for enrollment to patients with
- 1y agoACETAdicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Business WireAdicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards
- 1y agoACETAdicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences ConferenceBusiness WireAdicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President
- 1y agoACETAdicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual MeetingBusiness WireAdicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of an abstract
- 1y agoACETAPREAdicet Bio Appoints Michael Grissinger to the Board of DirectorsBusiness Wire--Mr. Grissinger brings more than four decades of leadership experience in pharmaceutical business development and strategic transactions-- Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company
- 1y agoACETAdicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireAdicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards
- 1y agoACETAdicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual ConferenceBusiness WireAdicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President
- 1y agoACETAdicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company ProgressBusiness WirePhase 1 clinical trial of ADI-001 in autoimmune diseases ongoing; on track to report preliminary clinical data from lupus nephritis (LN) patient cohort in 1H25 Additional LN clinical data and preliminary clinical data
- 1y agoACETAdicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific MeetingBusiness WireAdicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of two
- 1y agoACETAdicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)Business WireAdicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug
- 1y agoACETAdicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal InvolvementBusiness WireAdicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug
- 1y agoACETAdicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Business WireAdicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards
- 1y agoACETAdicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech ConferenceBusiness WireAdicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President